CSPG4 is expressed in 70% of the melanomas with a low and restricted expression profile in healthy tissue.133 Monoclonal antibodies designed against this target which can engage the FcRs on immune cells, including monocytes and macrophages, are under development in preclinical models. The gene discussed is CSPG4; the disease is melanoma.